Workflow
创芯国际获近亿元B轮融资,粤科基金和投控东海旗下中山浩创基金联合领投
Sou Hu Cai Jing·2025-05-19 00:45

Core Insights - Chuangxin International Biotechnology (Guangzhou) Co., Ltd. has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Donghai Investment Control's Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [1][2] - The company focuses on personalized treatment, new drug development, and synthetic biology, establishing a comprehensive ecosystem covering the entire lifecycle of organoids [1] - Chuangxin International aims to drive the organoid industry towards intelligent, standardized, and industrialized development, leveraging its advanced technology platform and multi-dimensional data intelligence system [1] Company Overview - Chuangxin International is headquartered in Guangzhou and has established joint R&D centers in Beijing, Shanghai, Macau, and Milan, Italy [1] - The company is recognized as a full-industry chain enterprise in the organoid field, focusing on three strategic directions: precision medicine, new drug development, and intelligent manufacturing [1] Investment Perspective - Yueke Fund highlights the significant application value of Chuangxin International's leading organoid technology in precision medicine and new drug development, aligning with their investment philosophy focused on core technology sectors [2] - Donghai Investment Control emphasizes the company's technological depth and growth potential, viewing this investment as a key part of their strategic layout in the biomedicine sector [2] Future Plans - The CEO of Chuangxin International expresses gratitude for the support from investors and outlines plans to leverage this financing round to enhance core technology research and product innovation [2] - The company aims to create a product matrix in key areas such as organoid intelligent devices, chips, and data intelligence systems, driving technological breakthroughs and industrial upgrades [2]